WuXi Biologics (Cayman) Inc. has announced a strategic collaboration with Virogen Biotechnology Inc. to advance the development and commercialization of VG712, Virogen's lead clinical-stage asset. Under this partnership, WuXi Biologics will provide comprehensive services, including technology transfer, process validation, and commercial manufacturing for both the drug substance and drug product of VG712. This collaboration aims to accelerate VG712's path to global market approval. VG712, a first-in-class anti-CD3 immunotoxin, is designed to restore immune function by depleting the patient's existing T cell pool, a strategy known as immunological reset. The drug has received Fast Track designation from the U.S. Food and Drug Administration, and a pivotal Phase II trial is currently underway. A Biologics License Application submission is anticipated between 2027 and 2028. No results from this trial have been presented yet.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。